For Drugmakers, The Sky's No Longer The LimitJoseph Weber
Drug companies pay attention to Linda M. Rhodes. As head of Pennsylvania's Department of Aging, she runs a $220 million-a-year program to help the Keystone State's elderly pay for drugs--the largest such program in the U.S. So, when Rhodes called Bristol-Myers Squibb Co. Chief Executive Richard L. Gelb last fall, he listened. Rhodes chastised Gelb for threatening to stay out of her program rather than absorb the 12.5% rebate off wholesale prices that a new Pennsylvania law requires. Gelb relented and signed up before the law took effect on Jan. 1. Soon, "a few other companies that were sitting on the fence" did the same, says Rhodes.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Ford to Take $267 Million Hit From Recall of F-Series Trucks
- Facebook and Google Helped Anti-Refugee Campaign in Swing States
- Turns Out It Will Be Congress's Fault When Stocks Crash